Arrowhead Pharmaceuticals

This early-stage study tests a new drug called ARO-INHBE in 180 adults with obesity, some of whom also have type 2 diabetes. The main goal is to check safety and how the drug moves through the body. Researchers will also see if it helps with weight loss, either alone or with anot…

This study is testing an experimental drug called ARO-MAPT-SC in healthy volunteers and people with early Alzheimer's disease. The goal is to see if the drug is safe and how the body processes it. The drug works by targeting a protein linked to Alzheimer's, with the hope of slowi…

This study is testing a new medicine called ARO-ATXN2 for people with spinocerebellar ataxia type 2, a rare genetic brain disorder that affects movement and coordination. The main goal is to check if the drug is safe and how the body processes it. About 36 adults will get either …

This study tests an experimental drug called ARO-DUX4 in 60 adults and teens with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a genetic condition that causes muscle weakness. The main goal is to check the drug's safety and how it moves through the body. Participants re…

This study tests a new medicine called zodasiran in people aged 12 and older with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol. The goal is to see if the drug safely lowers bad cholesterol levels over 12 months. Part…

This study is for adults with very high triglycerides, a type of fat in the blood that can increase the risk of pancreatitis and heart disease. Participants who completed a previous related study can join and will receive injections of plozasiran every 3 months for 2 years. The g…

This early-stage study tests a new drug called ARO-ALK7 in 138 adults with obesity, some of whom also have type 2 diabetes. The goal is to check if the drug is safe and how it affects weight and blood sugar. Participants receive either the drug or a placebo, and some may also tak…

This study tests an experimental drug called ARO-DM1 in 78 adults with type 1 myotonic dystrophy, a genetic muscle disorder. The main goal is to see if the drug is safe and how it moves through the body. Participants receive either the drug or a placebo, and the study is still re…

This early-stage study tests a new medicine called ARO-DIMERPA in 78 adults with mixed hyperlipidemia (high cholesterol and high triglycerides). The main goal is to check safety and how well the drug lowers harmful blood fats. Participants receive either the drug or a placebo, an…

This program provides plozasiran to people with familial chylomicronemia syndrome (FCS) or severe high triglycerides (SHTG) who are not well-controlled on standard treatments. Participants receive injections every 3 months for 15-21 months. The goal is to lower triglyceride level…

This study tests a new drug called plozasiran in about 288 adults with severely high triglycerides who have had pancreatitis before. Participants get either the drug or a placebo every three months. The goal is to see if the drug can prevent future pancreatitis attacks and lower …

This study tests an inhaled medicine called ARO-RAGE in 36 adults with mild asthma. The goal is to see if it can improve small airway function after breathing in an allergen. Participants will receive either the drug or a placebo and have their lung function measured over time.